Retail Investors Who Own 46% Along With Institutions Invested in Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Saw Increase in Their Holdings Value Last Week
Retail Investors Who Own 46% Along With Institutions Invested in Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Saw Increase in Their Holdings Value Last Week
Key Insights
关键见解
- Henan Lingrui Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- 50% of the business is held by the top 25 shareholders
- Institutional ownership in Henan Lingrui Pharmaceutical is 29%
- 河南灵瑞制药拥有大量散户投资者的所有权,这表明关键决策受广大公众股东的影响
- 50% 的业务由前 25 名股东持有
- 河南凌瑞药业的机构所有权为29%
To get a sense of who is truly in control of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285), it is important to understand the ownership structure of the business. With 46% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要了解谁真正控制了河南凌瑞药业有限公司(SHSE: 600285),了解业务的所有权结构非常重要。散户投资者拥有该公司的最大股份,拥有46%的股份。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。
While retail investors were the group that benefitted the most from last week's CN¥496m market cap gain, institutions too had a 29% share in those profits.
尽管散户投资者是从上周4.96亿元人民币的市值增长中受益最大的群体,但机构在这些利润中也占有29%的份额。
Let's delve deeper into each type of owner of Henan Lingrui Pharmaceutical, beginning with the chart below.
让我们从下图开始,深入研究河南凌瑞制药的每种所有者。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240310/0-291dad98a4ed91cf809619f303f2b02f-0-28dd03dff550485d4563de407edc08a8.png/big)
What Does The Institutional Ownership Tell Us About Henan Lingrui Pharmaceutical?
关于河南灵瑞药业,机构所有权告诉我们什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构根据近似于当地市场的指数来衡量自己的表现。因此,他们通常会更多地关注主要指数中包含的公司。
Henan Lingrui Pharmaceutical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Henan Lingrui Pharmaceutical's earnings history below. Of course, the future is what really matters.
河南灵瑞制药已经在股份登记处设立了机构。事实上,他们拥有该公司可观的股份。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这一事实,因为机构有时会像所有人一样进行不良投资。如果多家机构同时改变对股票的看法,你可能会看到股价快速下跌。因此,值得在下面查看河南凌瑞制药的收益记录。当然,未来才是真正重要的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240310/0-291dad98a4ed91cf809619f303f2b02f-1-6e42baffb6545ee9c61ed4298f65455c.png/big)
Henan Lingrui Pharmaceutical is not owned by hedge funds. Henan Lingrui Group Co., Ltd. is currently the largest shareholder, with 22% of shares outstanding. For context, the second largest shareholder holds about 4.9% of the shares outstanding, followed by an ownership of 4.5% by the third-largest shareholder. Additionally, the company's CEO Wei Xiong directly holds 0.6% of the total shares outstanding.
河南灵瑞制药不归对冲基金所有。河南凌锐集团有限公司目前是最大股东,已发行股份的22%。就背景而言,第二大股东持有约4.9%的已发行股份,其次是第三大股东持有4.5%的所有权。此外,该公司首席执行官熊伟直接持有已发行股份总额的0.6%。
Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.
我们的研究表明,前25名股东共同控制的公司股份不到一半,这意味着该公司的股票分布广泛,没有占主导地位的股东。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。分析师对该股的报道很少,但报道不多。因此,它还有获得更多报道的余地。
Insider Ownership Of Henan Lingrui Pharmaceutical
河南凌瑞药业的内部所有权
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
尽管内部人士的确切定义可能是主观的,但几乎每个人都认为董事会成员是内部人士。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。
Shareholders would probably be interested to learn that insiders own shares in Henan Lingrui Pharmaceutical Co., Ltd.. This is a big company, so it is good to see this level of alignment. Insiders own CN¥171m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.
股东们可能会有兴趣得知内部人士拥有河南凌瑞制药有限公司的股份。这是一家大公司,因此很高兴看到这种一致性。内部人士拥有价值1.71亿元人民币的股票(按当前价格计算)。大多数人会说,这表明股东和董事会之间的利益一致。尽管如此,可能值得检查一下这些内部人士是否一直在出售。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a 46% stake in Henan Lingrui Pharmaceutical. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
公众通常是个人投资者,持有河南凌瑞制药46%的股份。尽管这种所有权规模可能不足以影响对他们有利的政策决定,但它们仍然可以对公司政策产生集体影响。
Private Company Ownership
私人公司所有权
Our data indicates that Private Companies hold 24%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我们的数据表明,私人公司持有该公司24%的股份。可能值得对此进行更深入的研究。如果关联方,例如内部人士,对其中一家私营公司感兴趣,则应在年度报告中披露。私营公司也可能对公司有战略利益。
Next Steps:
后续步骤:
It's always worth thinking about the different groups who own shares in a company. But to understand Henan Lingrui Pharmaceutical better, we need to consider many other factors. For example, we've discovered 1 warning sign for Henan Lingrui Pharmaceutical that you should be aware of before investing here.
拥有公司股份的不同群体总是值得考虑的。但是,要更好地了解河南凌瑞药业,我们需要考虑许多其他因素。例如,我们发现了河南凌瑞制药的1个警告信号,在投资之前你应该注意这个信号。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
归根结底,未来是最重要的。您可以访问这份关于公司分析师预测的免费报告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。